targetId
stringlengths 15
15
| diseaseId
stringlengths 9
15
| nctid
stringlengths 11
11
⌀ | clinicalStatus
stringclasses 9
values | clinicalPhase
int64 0
4
| studyStartDate
stringlengths 10
10
⌀ | stopStatus
stringclasses 3
values | isStopped
stringclasses 1
value | phase4
stringclasses 1
value | phase3
stringclasses 1
value | phase2
stringclasses 1
value | id
int64 0
1,709B
| why_stopped
stringlengths 2
254
⌀ | phase
stringclasses 7
values | start_date
stringlengths 10
10
⌀ | status
stringclasses 3
values | last_update_posted_date
stringlengths 10
10
⌀ | completion_date
stringlengths 10
10
⌀ | prediction
stringclasses 15
values | metaprediction
stringclasses 6
values | max_l2g
float64 0.05
0.9
⌀ | l2g_075
stringclasses 1
value | l2g_05
stringclasses 1
value | l2g_025
stringclasses 1
value | l2g_01
stringclasses 1
value | l2g_005
stringclasses 1
value | taId
stringclasses 23
values | taLabel
stringclasses 24
values | taLabelSimple
stringclasses 2
values | gc
float64 0
5
⌀ | lof_tolerance
stringclasses 2
values | rnaDistribution
stringclasses 5
values | rnaSpecificity
stringclasses 5
values | partnersBin
stringclasses 4
values | datasourceId
stringclasses 22
values | datatypeId
stringclasses 7
values | total
int64 413k
413k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00006118 | Unknown status | 2 | 1999-07-01 | null | null | null | null | Phase II+ | 1,451,698,947,981 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00014274 | Completed | 2 | 2001-01-01 | null | null | null | null | Phase II+ | 1,503,238,553,647 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005958 | Unknown status | 2 | 1999-10-01 | null | null | null | null | Phase II+ | 1,529,008,358,766 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00479089 | Terminated | 2 | 2004-02-01 | Terminated | stopped | null | null | Phase II+ | 1,614,907,704,661 | Study halted due to drug sponsor decision to not continue. | Phase 2 | 29/02/2004 | Terminated | 01/11/2015 | 31/08/2014 | Business_Administrative | Business_Administrative | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003701 | Completed | 3 | 1999-03-01 | null | null | null | Phase III+ | Phase II+ | 1,649,267,441,761 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT01711112 | Completed | 2 | 2010-08-01 | null | null | null | null | Phase II+ | 25,769,804,181 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00005086 | Completed | 2 | 1999-08-01 | null | null | null | null | Phase II+ | 51,539,608,401 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00186277 | Completed | 2 | 2003-12-01 | null | null | null | null | Phase II+ | 77,309,412,247 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | 0 | LoF intolerant | Detected in many | Tissue enriched | from1to10 | slapenrich | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | cancer_biomarkers | affected_pathway | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | chembl | known_drug | 413,311 |
ENSG00000258947 | MONDO_0001187 | NCT00003105 | Completed | 1 | 1997-09-01 | null | null | null | null | null | 85,899,346,299 | null | null | null | null | null | null | null | null | null | null | null | null | null | null | MONDO_0045024 | cell proliferation disorder | Oncology | null | LoF intolerant | Detected in many | Tissue enriched | from1to10 | europepmc | literature | 413,311 |